AU2021359493A1 - Crystal forms of glp-1r agonists and uses thereof - Google Patents

Crystal forms of glp-1r agonists and uses thereof Download PDF

Info

Publication number
AU2021359493A1
AU2021359493A1 AU2021359493A AU2021359493A AU2021359493A1 AU 2021359493 A1 AU2021359493 A1 AU 2021359493A1 AU 2021359493 A AU2021359493 A AU 2021359493A AU 2021359493 A AU2021359493 A AU 2021359493A AU 2021359493 A1 AU2021359493 A1 AU 2021359493A1
Authority
AU
Australia
Prior art keywords
crystalline form
disease
compound
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021359493A
Other languages
English (en)
Other versions
AU2021359493A9 (en
Inventor
Pengyuan Chen
Wei Guo
Xiawei JIANG
Zheng Jane Li
Wenge Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu Regor Therapeutics Inc
Original Assignee
Qilu Regor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Regor Therapeutics Inc filed Critical Qilu Regor Therapeutics Inc
Publication of AU2021359493A1 publication Critical patent/AU2021359493A1/en
Publication of AU2021359493A9 publication Critical patent/AU2021359493A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2021359493A 2020-10-14 2021-10-13 Crystal forms of glp-1r agonists and uses thereof Pending AU2021359493A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120814 2020-10-14
CNPCT/CN2020/120814 2020-10-14
PCT/CN2021/123387 WO2022078352A1 (en) 2020-10-14 2021-10-13 Crystal forms of glp-1r agonists and uses thereof

Publications (2)

Publication Number Publication Date
AU2021359493A1 true AU2021359493A1 (en) 2023-06-15
AU2021359493A9 AU2021359493A9 (en) 2025-01-09

Family

ID=78401981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021359493A Pending AU2021359493A1 (en) 2020-10-14 2021-10-13 Crystal forms of glp-1r agonists and uses thereof

Country Status (9)

Country Link
US (1) US12516041B2 (https=)
EP (1) EP4228753B1 (https=)
JP (1) JP7769695B2 (https=)
CN (1) CN116710446B (https=)
AU (1) AU2021359493A1 (https=)
CA (1) CA3195264A1 (https=)
ES (1) ES3041328T3 (https=)
TW (1) TWI912388B (https=)
WO (1) WO2022078352A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210069000A (ko) * 2019-12-02 2021-06-10 현대약품 주식회사 Glp-1 수용체 작용제
KR20240068737A (ko) 2021-09-27 2024-05-17 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 벤즈이미다졸 카복실산
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
CN117362282B (zh) * 2022-07-07 2026-04-21 杭州德睿智药科技有限公司 Glp-1r激动剂的盐及其制备方法和应用
AU2023310481A1 (en) * 2022-07-18 2025-03-06 Mindrank Therapeutics (Suzhou) New Drug Research And Development Co., Ltd Polymorphic form of glp-1r agonist, preparation method therefor and use thereof
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US7727983B2 (en) 2008-03-07 2010-06-01 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP3555064B9 (en) * 2016-12-16 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
ES2943510T3 (es) * 2018-06-15 2023-06-13 Pfizer Agonistas del receptor GLP-1 y usos del mismo
CR20210341A (es) * 2018-11-22 2021-11-25 Qilu Regor Therapeutics Inc Agonistas de glp-ir y usos de los mismos
US10954221B2 (en) * 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof

Also Published As

Publication number Publication date
EP4228753C0 (en) 2025-07-30
JP2023546125A (ja) 2023-11-01
ES3041328T3 (en) 2025-11-11
EP4228753B1 (en) 2025-07-30
US12516041B2 (en) 2026-01-06
WO2022078352A1 (en) 2022-04-21
CA3195264A1 (en) 2022-04-21
AU2021359493A9 (en) 2025-01-09
US20230382899A1 (en) 2023-11-30
CN116710446A (zh) 2023-09-05
TWI912388B (zh) 2026-01-21
JP7769695B2 (ja) 2025-11-13
CN116710446B (zh) 2024-10-18
TW202227421A (zh) 2022-07-16
EP4228753A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
EP4157832B1 (en) Salt and crystal forms of glp-1r agonists and uses thereof
US12516041B2 (en) Crystal forms of GLP-1R agonists and uses thereof
TWI809334B (zh) ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式
CN112533674B (zh) Glp-1受体激动剂及其用途
TW202214622A (zh) Ｇｌｐ－１ｒ促效劑及其用途
US20250129057A1 (en) Solid Forms of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
EP4482577A1 (en) Compounds as glp-1r agonists
CN118401519A (zh) 作为glp-1r激动剂的化合物
HK40089377A (en) Crystal forms of glp-1r agonists and uses thereof
HK40089377B (en) Crystal forms of glp-1r agonists and uses thereof
HK40087545A (en) Salt and crystal forms of glp-1r agonists and uses thereof
HK40087545B (en) Salt and crystal forms of glp-1r agonists and uses thereof
TWI913272B (zh) Ｇｌｐ-１ｒ促效劑之鹽和晶型及其用途
CN104926706B (zh) 六氢并环戊二烯衍生物的盐及其制备方法和应用
HK40082417A (en) Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt

Legal Events

Date Code Title Description
SREP Specification republished